



Concerns: Gonorrhea Meds

The Food and Drug Administration approved two oral medications for gonorrhea.

February 16, 2026 By [Liz Highleyman](#)

The Food and Drug Administration approved two oral medications for gonorrhea in December, the first new classes of antibiotics for the sexually transmitted infection in decades. Gepotidacin (brand name Blujepa) and zoliflodacin (Nuzolvence) were approved to treat uncomplicated urogenital gonorrhea in adolescents and adults. Gonorrhea can cause painful urination and genital discharge, and it increases the likelihood of acquiring or transmitting HIV; if left untreated, it can lead to serious complications, including chronic pain and infertility. The Phase III EAGLE-1 trial, which enrolled more than 600 participants, showed that 93% of people randomized to receive gepotidacin were cured, as were 91% of those who received standard treatment. Another Phase III trial with more than 900 participants—22% of whom were living with HIV—found that 91% of those who received zoliflodacin and 96% of those on standard treatment were cured. The recent approvals help meet an urgent need, as gonorrhea is increasingly resistant to existing drugs.

© 2026 Smart + Strong All Rights Reserved.

<http://beta.docker.poz.com/article/concerns-gonorrhea-meds>